NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026 NImmune Biopharma a private late-stage precision inflammation and immunology (“I&I”) biopharmaceutical company, will present first-ever preclinical and translational data demonstrating the…
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease Lineage Cell Therapeutics, Inc. a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the expansion of its cell transplant pipeline…
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group Turn Therapeutics, Inc. a clinical-stage dermatology company developing novel therapies for inflammatory skin diseases, today announced it has entered into a growth capital loan facility with Avenue…
Artis BioSolutions Establishes U.S.-based Synthetic DNA Manufacturing Hub in Boston Artis BioSolutions an advanced therapies company dedicated to integrating the specialized technologies, infrastructure, and manufacturing capabilities required to deliver next-generation genetic medicines, today announced the establishment of new synthetic DNA…
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on…
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026 Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced partner…
Almirall’s 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology Almirall, a global biopharmaceutical company dedicated to medical dermatology, this weekend hosted the 17th edition of Skin Academy,…
Sakura Finetek Global and Hamamatsu Photonics K.K. Global Alliance Press Release Sakura Finetek Global, a worldwide leader in automated tissue and slide preparation solutions for anatomic pathology, and Hamamatsu Photonics K.K., a global leader in imaging technologies, today announced an…
California Public Utilities Commission Conditionally Approves RNG Procurement Contract from Anaergia’s SoCal Biomethane Facility Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG; OTCQX: ANRGF) reports that the California Public Utilities Commission (“CPUC”) has conditionally approved a long-term biomethane procurement contract…
Novartis to Acquire Synnovation Therapeutics’ Pan-Mutant Selective PI3Kα Inhibitor Program Synnovation Therapeutics, LLC (“Synnovation”), a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology and immunology today announced a definitive agreement for Novartis to acquire…
The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ® The 15-20 National Hospital (l’Hôpital national des 15-20) in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME…
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review Ionis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an…